Home » Services » Preclinical studies » Efficacy studies » Diabetic retinopathy
Diabetic retinopathy


  • Retinal vascular permeability: VEGF-induced fluorescein leakage
  • Retinal angiogenesis: animal model of oxygen-induced retinopathy (OIR)


  • Retinal vascular edema (diabetic macular edema, retinal vein occlusion)
  • Diabetic retinopathy (retinal angiogenesis)
  • Human retinopathy of prematury (ROP)

Administrations: topical ocular administration, intraviteal injection, intraperitoneal, sub-cutaneous injection 


Animals: pigmented rabbits, mice



  • In vivo retinal fluorescein leakage using scanning fluorophotometry
  • Histology

Reference substances: triamcinolone acetonide, dexamethasone, ranibizumab


If you need more information on others Iris Pharma’s animal models of Diabetic Retinopathy, please contact us at info@iris-pharma.com or call 33 4 93 59 49 59